Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors

This publication has 17 references indexed in Scilit:

• Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial
  European Urology, 2022
• Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
  Current Medical Research and Opinion, 2020
• Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies
  European Urology Oncology, 2019
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2018
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
  New England Journal of Medicine, 2015
• Radiotherapy for renal-cell carcinoma
  The Lancet Oncology, 2014
• Psychological distress among male patients and male spouses: what do oncologists need to know?
  Annals of Oncology, 2009
• Social Support and Chronic Kidney Disease: An Update
  Advances in Chronic Kidney Disease, 2007
• A review of human cell radiosensitivity in vitro
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
• Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
  Cancer, 1993